20 April 2017
Redx Pharma announces that it has appointed Mr Iain Ross as Chairman of its Board of Directors and as a Non-Executive Director of the Company, effective from 1 May 2017.
Mr Ross has over 35 years’ of experience having held Senior Board and Management positions at multiple public and private companies in the life sciences sector.
Currently Mr Ross serves as Non-Executive Chairman of AIM quoted e-Therapeutics plc and Biomer Technology Ltd alongside his Non-Executive Directorships at London listed Premier Veterinary Group plc, ASX quoted Anatara LifeSciences Ltd and Novogen Ltd, and as a Director of Aldershot Town Football Club.
Iain’s previous executive positions include Executive Chairman at Silence Therapeutics plc (2005-2010), Chief Executive Officer at Allergy Therapeutics (2001-2002), Chief Executive Officer at Quadrant Healthcare plc (1995-2000) and Main Board Director of Celltech Group plc and CEO of Celltech Biologics (1991-1995). He has also been a Non-Executive Director at Benitec Biopharma (2010-2016), Phadia AB (2004-2007) and Eden BioDesign (2003-2007). Prior to this he worked at several multinational companies including Sandoz AG, Fisons plc and Hoffman La Roche.
Mr Ross is a qualified Chartered Director (UK IoD) and Vice Chairman of Royal Holloway, London University.
Dr Neil Murray, Chief Executive Officer of Redx Pharma, commented on Iain’s appointment:
I am delighted to welcome Iain Ross to Redx Pharma as Chairman of the Board. His extensive experience in the life science sector makes him the ideal candidate to take on this role. I am confident that under his stewardship the Company will deliver shareholder value as we transition into a clinical-stage research and development company with a focus on cancer, immunology and infection.
Iain Ross, incoming Chairman of Redx Pharma, commented on his appointment:
Redx Pharma is a business of the highest quality that has discovered high value assets in cancer, immunology and infection and the opportunity to be part of progressing these promising assets through the clinic was instantly appealing. I look forward to working with the Board to realise the value of our best-in-class assets: RXC004 - Porcupine inhibitor and RXC005 - reversible BTK inhibitor, alongside several other promising assets in the Company’s pipeline.